NCT05291390View on ClinicalTrials.gov

Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)

PHASE2UnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 21, 2022

Primary Completion Date

February 29, 2024

Study Completion Date

March 31, 2024

Conditions
Acute Myeloid Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)
Interventions
DRUG

Pyronaridine Tetraphosphate

Via oral capsules.

Trial Locations (1)

B P 19 001

RECRUITING

Dalal Jamm Hospital, Guediawaye GOL SUD

Sponsors
All Listed Sponsors
collaborator

Uganda Cancer Institute

OTHER

collaborator

African Center for Cancer Research and End of Life Care (ACREOL), Rwanda

UNKNOWN

collaborator

Ifakara Health Research and Development Centre

OTHER

collaborator

Dalal Jamm Hospital, Dakar, Senegal

OTHER

lead

Armaceutica, Inc.

INDUSTRY